Navigation Links
Protein injection points to muscular dystrophy treatment
Date:11/27/2012

November 27, 2012 Ottawa Scientists have discovered that injecting a novel human protein into muscle affected by Duchenne muscular dystrophy significantly increases its size and strength, findings that could lead to a therapy akin to the use of insulin by diabetics. These results were published today in the Proceedings of the National Academy of Sciences by Dr. Julia von Maltzahn and Dr. Michael Rudnicki, the Ottawa scientist who discovered muscle stem cells in adults.

"This is an unprecedented and dramatic restoration in muscle strength," says Dr. Rudnicki, a senior scientist and director for the Regenerative Medicine Program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He is also a Canada Research Chair in Molecular Genetics and professor in the Faculty of Medicine at the University of Ottawa.

"We know from our previous work that this protein, called Wnt7a, promotes the growth and repair of healthy muscle tissue. In this study we show the same types of improvement in a mouse model of Duchenne muscular dystrophy. We found that Wnt7a injections increased muscle strength almost two-fold, to nearly normal levels. We also found that the size of the muscle fibre increased and there was less muscle damage, compared to mice not given Wnt7a."

Duchenne muscular dystrophy is a genetic disorder that affects one of every 3,500 newborn males. In Canada, all types of muscular dystrophy affect more than 50,000 people. The disease often progresses to a state where the muscles are so depleted that the person dies due to an inability to breath. For people with Duchenne muscular dystrophy, this usually happens in their 20s or 30s.

"This is also exciting because we think it's a therapeutic approach that could apply to other muscle-wasting diseases," says Dr. Rudnicki.

Dr. Rudnicki's lab is a world leader in research on muscle stem cells. They have contributed significantly to our underst
'/>"/>

Contact: Paddy Moore
padmoore@ohri.ca
613-737-8899 x73687
Ottawa Hospital Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. IU biologists offer clearer picture of how protein machine systems tweak gene expression
2. Making memories: How 1 protein does it
3. Embryonic development protein active in cancer growth
4. More effective method of imaging proteins
5. The loss of a protein makes jump the tumor to the lymph node
6. Gold nanoantennas detect proteins
7. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
8. New hope for treating Alzheimers Disease: A role for the FKBP52 protein
9. Protein jailbreak helps breast cancer cells live
10. Plant research reveals new role for gene silencing protein
11. Newly found protein helps cells build tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... After a year of studying up close the symbiotic relationship ... University biologist has advanced the scientific understanding of biological diversity. ... relationship between two or more organisms that can be parasitic ... diversity as predation and competition. The Proceedings ...
... , Feb. 5, 2013 Reportlinker.com ... is available in its catalogue: ... and Prognostic Biomarkers, 2013 ... Endothelial Growth Factor (VEGF), which plays an ...
... When it comes to gene sequencing and personalized medicine for ... proteins are relatively easy to target with drugs and plenty ... study, University of Michigan Comprehensive Cancer Center researchers assess the ... kinases are acting up in a particular tumor. They go ...
Cached Biology News:Pirate-like flies connect symbiosis to diversity 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5Study finds potential to match tumors with known cancer drugs 2Study finds potential to match tumors with known cancer drugs 3
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology and medical device ... and the United States , today ... first quarter of 2015 after the New York Stock ... be Thursday morning, May 14, 2015 Shanghai time). The ...
(Date:4/23/2015)... 23, 2015 Glemser Technologies ... first EMC® Enterprise Content Division (ECD) Certified Solution ... EMC Documentum® for Life Sciences Solution Suite . ... and capabilities to provide life sciences companies of ... , The EMC Documentum Solution Suite offers four ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Firmenich,s world leadership in the ... flavor ingredients, - New S2383 flavor enhancer may be used in ... healthcare products to reduce the need for sucralose, ... Inc. (Nasdaq: SNMX ), a leading company,focused on using proprietary ...
... BOSTON, Nov. 6 Solos Endoscopy, Inc. (Pink,Sheets: SNDY) ... a,significant purchase order for laparoscopic instruments from the St. ... client of Solos,Endoscopy,s for over 19 yrs and it ... Saint Mary,s Hospital has played a vital role in ...
... Inc. (NTI(R)) (Nasdaq: NTII ) today announced its ... first quarter of the,company,s fiscal year ending June 30, ... was $3.6 million, compared to $3.9 million for the,three ... million,for the first quarter of fiscal 2009 compared to ...
Cached Biology Technology:SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
...
... The Beacon 2000 One-Step FP Standardization ... high and low fluorescence polarization values ... of the Beacon 2000 System. It ... polarization values generated by their instrument ...
... Engineered with new technology incorporating ... for unsurpassed flexibility, the new Varian ... advanced spectrometer available today., ,The Varian ... each transmitter and receiver channel, providing ...
Biology Products: